These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20860064)

  • 21. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response.
    Souza RP; Romano-Silva MA; Lieberman JA; Meltzer HY; Wong AH; Kennedy JL
    Psychopharmacology (Berl); 2008 Oct; 200(2):177-86. PubMed ID: 18500637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy].
    Ewald HL; Mors NP; Rosenberg R
    Ugeskr Laeger; 1996 Jun; 158(25):3601-3. PubMed ID: 8693618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia.
    Kang SG; Park YM; Choi JE; Lim SW; Lee HJ; Lee SH; Kim YK; Kim SH; Cho SN; Kim L
    Hum Psychopharmacol; 2010 Jul; 25(5):397-403. PubMed ID: 20589923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of a polymorphism in the NRXN3 gene with the degree of smoking in schizophrenia: a preliminary study.
    Novak G; Boukhadra J; Shaikh SA; Kennedy JL; Le Foll B
    World J Biol Psychiatry; 2009; 10(4 Pt 3):929-35. PubMed ID: 19658047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resequencing and association analysis of coding regions at twenty candidate genes suggest a role for rare risk variation at AKAP9 and protective variation at NRXN1 in schizophrenia susceptibility.
    Suárez-Rama JJ; Arrojo M; Sobrino B; Amigo J; Brenlla J; Agra S; Paz E; Brión M; Carracedo Á; Páramo M; Costas J
    J Psychiatr Res; 2015; 66-67():38-44. PubMed ID: 25943950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of reelin (RELN) single nucleotide polymorphism rs7341475 with prepulse inhibition in the Jewish Israeli population.
    Greenbaum L; Levin R; Lerer E; Alkelai A; Kohn Y; Heresco-Levy U; Ebstein RP; Lerer B
    Biol Psychiatry; 2011 Mar; 69(5):e17-8; author reply e19. PubMed ID: 21195391
    [No Abstract]   [Full Text] [Related]  

  • 27. Selected single-nucleotide variants in GRIN1, GRIN2A, and GRIN2B encoding subunits of the NMDA receptor are not biomarkers of schizophrenia resistant to clozapine: exploratory study.
    Krzystanek M; Asman M; Witecka J; Pałasz A; Wiaderkiewicz R
    Pharmacol Rep; 2021 Feb; 73(1):309-315. PubMed ID: 33025395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exon-disrupting deletions of NRXN1 in idiopathic generalized epilepsy.
    Møller RS; Weber YG; Klitten LL; Trucks H; Muhle H; Kunz WS; Mefford HC; Franke A; Kautza M; Wolf P; Dennig D; Schreiber S; Rückert IM; Wichmann HE; Ernst JP; Schurmann C; Grabe HJ; Tommerup N; Stephani U; Lerche H; Hjalgrim H; Helbig I; Sander T;
    Epilepsia; 2013 Feb; 54(2):256-64. PubMed ID: 23294455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resequencing and follow-up of neurexin 1 (NRXN1) in schizophrenia patients.
    Mühleisen TW; Basmanav FB; Forstner AJ; Mattheisen M; Priebe L; Herms S; Breuer R; Moebus S; Nenadic I; Sauer H; Mössner R; Maier W; Rujescu D; Ludwig M; Rietschel M; Nöthen MM; Cichon S
    Schizophr Res; 2011 Apr; 127(1-3):35-40. PubMed ID: 21288692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.
    Huang E; Maciukiewicz M; Zai CC; Tiwari AK; Li J; Potkin SG; Lieberman JA; Meltzer HY; Müller DJ; Kennedy JL
    Pharmacogenomics; 2016; 17(2):103-9. PubMed ID: 26666695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia.
    Xu M; Xing Q; Li S; Zheng Y; Wu S; Gao R; Yu L; Guo T; Yang Y; Liu J; Zhang A; Zhao X; He G; Zhou J; Wang L; Xuan J; Du J; Li X; Feng G; Lin Z; Xu Y; St Clair D; Lin Z; He L
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1026-32. PubMed ID: 20580759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine.
    Malhotra AK; Goldman D; Ozaki N; Breier A; Buchanan R; Pickar D
    Am J Psychiatry; 1996 Aug; 153(8):1092-4. PubMed ID: 8678181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.
    Arranz MJ; Munro J; Owen MJ; Spurlock G; Sham PC; Zhao J; Kirov G; Collier DA; Kerwin RW
    Mol Psychiatry; 1998 Jan; 3(1):61-6. PubMed ID: 9491814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine.
    Taylor DL; Tiwari AK; Lieberman JA; Potkin SG; Meltzer HY; Knight J; Remington G; Müller DJ; Kennedy JL
    Hum Psychopharmacol; 2016 Mar; 31(2):121-34. PubMed ID: 26876050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.
    Masellis M; Basile V; Meltzer HY; Lieberman JA; Sevy S; Macciardi FM; Cola P; Howard A; Badri F; Nöthen MM; Kalow W; Kennedy JL
    Neuropsychopharmacology; 1998 Aug; 19(2):123-32. PubMed ID: 9629566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response.
    Tsai SJ; Hong CJ; Yu YW; Lin CH; Song HL; Lai HC; Yang KH
    Schizophr Res; 2000 Sep; 44(3):177-81. PubMed ID: 10962219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects.
    Kohn Y; Ebstein RP; Heresco-Levy U; Shapira B; Nemanov L; Gritsenko I; Avnon M; Lerer B
    Eur Neuropsychopharmacol; 1997 Feb; 7(1):39-43. PubMed ID: 9088883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.
    Hwang R; Shinkai T; De Luca V; Müller DJ; Ni X; Macciardi F; Potkin S; Lieberman JA; Meltzer HY; Kennedy JL
    Psychopharmacology (Berl); 2005 Aug; 181(1):179-87. PubMed ID: 15830237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic regulation of Nrxn1 [corrected] expression: an integrative cross-species analysis of schizophrenia candidate genes.
    Mozhui K; Wang X; Chen J; Mulligan MK; Li Z; Ingles J; Chen X; Lu L; Williams RW
    Transl Psychiatry; 2011 Jul; 1(7):e25. PubMed ID: 22832527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rare NRXN1 promoter variants in patients with schizophrenia.
    Shah AK; Tioleco NM; Nolan K; Locker J; Groh K; Villa C; Stopkova P; Pedrosa E; Lachman HM
    Neurosci Lett; 2010 May; 475(2):80-4. PubMed ID: 20347009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.